

Proskauer Rose Represents the Wellcome Trust in €25 Million Financing of Endotis Pharma

January 22, 2008

January 22, 2008 (Paris, France) - Proskauer Rose LLP, an international law firm with more than 750 lawyers worldwide, announced that it represented The Wellcome Trust in its involvement in a €25 million financing of Endotis Pharma, a French pharmaceutical company dedicated to the discovery and development of small glycol drugs for use in thrombosis and oncology treatment.

The Wellcome Trust, the largest charity in the United Kingdom and the second-largest medical research charity in the world, acted as lead investor in the transaction. Other investors included Sofinnova Partners, Endeavour Vision, Organon, and NIF SMBC Ventures Co.

The Proskauer team representing The Wellcome Trust included Guillaume Kellner, Etienne Mathey, and Sarah Cherry.

Proskauer's Paris office provides French and European Union legal advice. Its core practices include: general corporate transactions including mergers and acquisitions, private equity, corporate restructurings, and joint ventures; commercial law including competition law matters, distribution, and licensing; labor law, with a particular emphasis on large corporate reorganizations and litigation; tax including international taxation of companies and individuals, tax structuring of corporate transactions and investment funds, and personal tax planning; and commercial litigation including appearances before various French courts and international arbitration tribunals and acting as "instructing solicitor" in cases before courts and jurisdictions in which the firm is not admitted.

Related Professionals

• Sarah K. Cherry
Partner